Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Free Cash Flow for 7 consecutive years, with -$28.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 37.71% year-over-year to -$28.8 million, compared with a TTM value of $106.0 million through Dec 2025, up 165.08%, and an annual FY2025 reading of $106.0 million, up 165.08% over the prior year.
  • Free Cash Flow was -$28.8 million for Q4 2025 at Keros Therapeutics, down from $4.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $160.6 million in Q1 2025 and bottomed at -$46.3 million in Q4 2024.
  • Average Free Cash Flow over 5 years is -$15.8 million, with a median of -$24.8 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 2142.5% in 2023, then soared 452.93% in 2025.
  • Year by year, Free Cash Flow stood at -$19.7 million in 2021, then decreased by 10.49% to -$21.8 million in 2022, then decreased by 10.74% to -$24.1 million in 2023, then tumbled by 91.83% to -$46.3 million in 2024, then surged by 37.71% to -$28.8 million in 2025.
  • Business Quant data shows Free Cash Flow for KROS at -$28.8 million in Q4 2025, $4.5 million in Q3 2025, and -$30.3 million in Q2 2025.